Anticoagulation Stewardship Program in the DOAC Era

Area of Science:

• Pharmacology and Therapeutics
• Hematology
• Clinical Pharmacy

Background:

• Direct oral anticoagulants (DOACs) offer significant antithrombotic benefits but pose bleeding risks requiring effective reversal agents.
• Recent regulatory actions, including the U.S. market withdrawal of andexanet alfa, have critically impacted DOAC reversal strategies.
• Anticoagulation stewardship programs (ASPs) are vital for managing DOACs and their reversal in the evolving clinical landscape.

Purpose of the Study:

• To review the current landscape of DOAC reversal agents and strategies.
• To analyze the impact of regulatory changes, specifically the andexanet alfa withdrawal, on clinical practice.
• To provide guidance for anticoagulation stewardship programs in optimizing DOAC reversal.

Main Methods:

• A narrative review synthesizing data from key clinical trials (RE-VERSE AD, ANNEXA-4, ANNEXA-I).
• Inclusion of current clinical guidelines and emerging research on reversal agents.
• Critical analysis of regulatory updates, including the FDA's withdrawal of andexanet alfa.

Main Results:

• Idarucizumab remains the sole FDA-approved specific antidote for dabigatran.
• Following andexanet alfa's withdrawal, 4-factor and activated prothrombin complex concentrates (PCCs) are primary reversal agents for Factor Xa inhibitors, showing comparable efficacy.
• Ciraparantag, a universal reversal agent, is in Phase III development, offering future potential.

Conclusions:

• The departure of andexanet alfa has fundamentally altered DOAC reversal protocols.
• Optimizing PCC-based strategies and enhancing ASPs are crucial for managing DOAC-associated bleeding.
• Institutions must update algorithms, ensure PCC availability, and prepare for novel universal antidotes.